ArticleACS pharmacology & translational science2025
Targeting α‑Klotho Protein by Agmatine and Pioglitazone Is a New Avenue against Diabetic Nephropathy.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in understanding the NLRP3 inflammasome‑mediated mechanisms and therapeutic targets in diabetic nephropathy (Review).International journal of molecular medicine · 2026Review
- Current Controversies on Adequate Circulating Vitamin D Levels in CKD.International journal of molecular sciences · 2025Review
- Probiotics and the Gut-Brain Axis: Emerging Therapeutic Strategies for Epilepsy and Depression Comorbidity.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a common microvascular complication of diabetes mellitus (DM). Several mechanisms have been proposed for DN pathogenesis; however, it remains a progressive risk for DM patients. For the first time, the current study aimed to investigate the nephroprotective effects of agmatine and pioglitazone through modulating α-klotho, anti-ERS, anti-inflammatory, and antipyroptotic properties in ameliorating DN. A single intraperitoneal injection of streptozotocin (STZ) (52.5 mg/kg), preceded by nicotinamide (NA) (50 mg/kg, i.p.), induced DN. NA provided partial protection to insulin-secreting β-cells against the severe damage caused by STZ. Agmatine (100 mg/kg, i.p.) was injected daily for 6 weeks after modeling DN, either alone or in combination with pioglitazone (5 mg/kg, p.o.). DN rats showed a marked decrease in blood glucose (BG) levels, body weight, serum urea levels, serum creatinine (Cr) levels, and histopathological alterations, besides reducing renal α-klotho content associated with upregulating ATF4/IRE1α/NLRP3 renal content along with increasing HMGB1/NF-κB protein expression. On the contrary, agmatine and pioglitazone improved animals' body weights, BG, serum urea, and Cr levels. Moreover, agmatine and pioglitazone inhibited renal NLRP3 content, reducing oxidative stress and inflammatory cascades. They also upregulated renoprotective α-klotho and decreased renal ATF4/IRE1α/TXNIP/NLRP3 content associated with a decrease in renal HMGB1/NF-κB protein expression. Briefly, besides its antidiabetic effect, agmatine, along with pioglitazone, shows promise as a treatment for DM and DN via mediating α-klotho/ERS/HMGB1/NF-κB/NLRP3 inflammasome signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.